Elizma Snyman

DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

Evgeny V. Morozov, V. G. Abramov, T. Welte, 2022, Infection.